Navigation Links
Par Pharmaceutical Announces Results of Its 'Modified Dutch Auction' Tender Offer
Date:11/25/2009

7-5360 (Toll Free) and (212) 440-9800 for banks and brokerage firms.

About Par Pharmaceutical

Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press releases and other company information, visit www.parpharm.com.

Forward-Looking Statements

This press release also contains "forward-looking statements" that are based on current expectations, estimates, beliefs, assumptions and projections about our business. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Risk factors that might affect such forward-looking statements include those set forth in our Schedule TO filed with the SEC on October 14, 2009 (as amended), in Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2008, in Item 1A of the Company's subsequent Quarterly Reports on Form 10-Q, in other of the Company's filings with the SEC from time to time, including Current Reports on Form 8-K, and on general industry and economic conditions. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.

SOURCE Par Pharmaceutical Companies, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 Triad Semiconductor, Inc. today ... of Intersil and former President of Linear Technology Corporation ... “David has extraordinary technology and business expertise, and we ... directors,” said Lynn Hayden, Triad CEO and chairman. , ... and mixed signal semiconductor experience to Triad's board. From ...
(Date:9/15/2014)... 16, 2014 The team of defective ... Danis & Lowe report that the company behind ... responsible for the injuries that a woman sustained after ... stress urinary incontinence (SUI). , Carey Danis & Lowe ... litigation and personal injury law. The St. Louis law ...
(Date:9/15/2014)... iFitDress.com, one of the most distinguished dress companies, has ... dresses to its online store. In addition, the company ... They are now provided at very low prices, up to ... confidence in the newly unveiled sapphire evening outfits. “I believe ... all over the world. Up to now, over 200 items ...
(Date:9/15/2014)... 2014 Imaging can be a cost-effective ... might benefit from aggressive intervention, according to a new ... , The study looked at people with asymptomatic carotid ... supplying blood to the head due to atherosclerosis, or ... of up to 20 percent of ischemic strokes, which ...
(Date:9/15/2014)... September 15, 2014 Ticket Down ... tickets for her 2015 Honeymoon Tour. Ariana Grande ... of Boca Raton, Florida has been active in the music ... album, which reached the top of the charts in the ... Association of America for selling more than 400,000 copies. Less ...
Breaking Medicine News(10 mins):Health News:David Bell Joins Triad Semiconductor's Board of Directors 2Health News:Carey Danis & Lowe Reports On $73 Million Boston Scientific Verdict 2Health News:Beautiful Sapphire Evening Dresses Provided By iFitDress.com 2Health News:RSNA: Imaging Identifies Asymptomatic People at Risk for Stroke 2Health News:RSNA: Imaging Identifies Asymptomatic People at Risk for Stroke 3Health News:Ariana Grande Tickets in Fairfax, Uncasville, Philadelphia, Orlando, San Jose, Miami, New York, Detroit, Saint Paul, Chicago, San Antonio, Pittsburgh, Atlanta & Dallas 2Health News:Ariana Grande Tickets in Fairfax, Uncasville, Philadelphia, Orlando, San Jose, Miami, New York, Detroit, Saint Paul, Chicago, San Antonio, Pittsburgh, Atlanta & Dallas 3
... ... , ... May 6, 2010 -- CosmoCom the global leader in Contact Center Consolidation 2.0, ... 2010 Long Island Software Award (LISA). Presented by the Long Island Software and Technology ...
... ... are many Americans struggling to find steady employment in a highly competitive market. In order ... to provide a more youthful, refreshed appearance. Non-surgical med spa treatments can offer many benefits ... ...
... ... are interested in achieving top performance from GPUs in diverse applications using Monte Carlo ... the Numerical Algorithms Group (NAG). , ... (Vocus) May 6, 2010 -- Developers and researchers who are interested ...
... In ... leading online fresh-from-the-farm food and grocery delivery service, is celebrating Nurse Appreciation Week (May ... to nurses at five community hospitals in Westchester and Greenwich, CT. , ... Long Island City, NY ...
... ... its corporate headquarters to King Farm in Rockville, Maryland. The move comes at a time ... ... comprehensive HR solutions, recently announced plans to move its corporate headquarters to King Farm in ...
... There,s no safe amount of alcohol for women during this ... Pregnant woman may have another reason to avoid drinking, with ... the risk for a rare blood cancer in children. , ... acute myeloid leukemia (AML), an often fatal blood cancer, increased ...
Cached Medicine News:Health News:CosmoCom Wins Software Award for CosmoHealth 2Health News:CosmoCom Wins Software Award for CosmoHealth 3Health News:Med Spa Treatments Become More Popular as Unemployment Rates Climb 2Health News:Med Spa Treatments Become More Popular as Unemployment Rates Climb 3Health News:More GPU Routines for Technical Research Now Available from Numerical Algorithms Group 2Health News:More GPU Routines for Technical Research Now Available from Numerical Algorithms Group 3Health News:FreshDirect Celebrates Nurse Appreciation Week with Delivery of Complimentary 4-Minute Meals for Nurses at Hospitals in Westchester and Greenwich, CT 2Health News:FreshDirect Celebrates Nurse Appreciation Week with Delivery of Complimentary 4-Minute Meals for Nurses at Hospitals in Westchester and Greenwich, CT 3Health News:Astra HR Moves its Corporate Headquarters to King Farm, Rockville, MD 2Health News:Astra HR Moves its Corporate Headquarters to King Farm, Rockville, MD 3Health News:Drinking While Pregnant Tied to Rare Leukemia in Offspring 2Health News:Drinking While Pregnant Tied to Rare Leukemia in Offspring 3
(Date:9/15/2014)... , Sept. 15, 2014  Decision Resources ... Physician™ 2014, finds that online information and ... brands to differentiate their offering and support ... device purchasing decisions rely on websites, mobile ... about devices—and these physicians are looking to ...
(Date:9/15/2014)... MINNEAPOLIS , Sept. 15, 2014 ... a non-profit professional association serving more than 4,500 ... released its 2015 SCALENDAR, which chronicles corporate fines ... compliance and ethics professionals have a ready reference ... "We developed the SCALENDAR to help ...
(Date:9/15/2014)... -- Research and Markets has announced the addition ... Tests, 9th Edition" report to their offering. ... testing market and all of its segments, providing customers with ... For Business Planning. This is the ninth edition ... 2013 and early 2014. New entrants, new technologies have entered ...
Breaking Medicine Technology:Physician device decision-makers show strong demand for device manufacturer digital content and support 2Physician device decision-makers show strong demand for device manufacturer digital content and support 3More than $55 billion in fines and settlements added by SCCE to its 2015 Corporate Scandal Calendar 2The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 2The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 3
... 2012 Mylan Inc. (Nasdaq: MYL ) today announced its ... Financial Results Adjusted diluted EPS of ... for the same prior year period, an increase of 18%; ... 31, 2011 compared to $1.61 for the prior year, an increase of ...
... CITY, N.J., Feb. 21, 2012 S1 Pharmaceuticals, Inc. ... New Drug (IND) application to the U.S. Food and ... (Lorexys).  Lorexys is the Company,s lead drug candidate for ... Female Sexual Dysfunction (FSD).  Lorexys, clinical ...
Cached Medicine Technology:Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 2Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 3Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 4Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 5Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 6Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 7Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 8Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 9Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 10Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 11Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 12Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 13Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 14Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 15Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 16S1 Pharmaceuticals Announces IND Filing of SIP-104 (Lorexys) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) 2
For the quantitative in vitro determination of Uric Acid in serum, plasma and urine...
For the quantitative in vitro determination of apolipoprotein A-1 (apo A-1) in serum and plasma. For use as an aid if assessing the risk of coronary artery disease....
For the quantitative in vitro determination of Urea in serum, plasma and urine....
The XTRI method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of triglycerides in serum and plasma....
Medicine Products: